Sino Biopharmaceutical Limited (SBHMY) ist ein börsennotiertes Unternehmen im Gesundheitswesen Sektor, tätig in der Biotechnologie Branche. Der Hauptsitz des Unternehmens ist in Wan Chai, Hong Kong. Der aktuelle CEO ist S. Y. Tse.
SBHMY hat IPO-Datum 2017-09-05, 24,379 Vollzeitbeschäftigte, gelistet an der Other OTC, eine Marktkapitalisierung von $14.2B.
Sino Biopharmaceutical Limited is an investment holding company and research and development pharmaceutical conglomerate headquartered in Hong Kong, operating primarily in the People's Republic of China. The company develops and commercializes a diverse portfolio of pharmaceutical products across multiple therapeutic areas, including oncology, cardio-cerebral vascular, hepatitis, orthopedic, and respiratory medicines, as well as advanced chemical formulations and generic pharmaceuticals. Beyond pharmaceutical manufacturing, the company operates an integrated healthcare ecosystem encompassing hospital operations, pharmaceutical distribution, optometry services, health food production, medical device development, and health information consultancy. Through its three main business segments—Modernised Chinese Medicines and Chemical Medicines, Investment, and Others—Sino Biopharmaceutical serves patients and healthcare providers across China with both traditional and contemporary therapeutic solutions. The company was incorporated in 2000 and maintains a comprehensive value chain from research and development through distribution and patient care services.
